- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Top 3 Canadian Biotech Stocks (Updated July 2022)
Which biotech stocks on the TSXV are performing the best in 2022? Here’s a look at the three top Canadian biotech stocks.
Company | Description |
---|---|
1. Hemostemix (TSXV:HEM) | Market cap: C$16.722 million; year-to-date gain: 37.5 percent Hemostemix is a clinical-stage autologous stem cell therapy company. Founded in 2003, the firm develops, manufactures and commercializes blood-derived cell therapies from each patient's own blood. Hemostemix’s lead product, ACP-01, is designed for the treatment of critical limb ischemia, peripheral artery disease, angina, ischemic cardiomyopathy and dilated cardiomyopathy. Shares of the top Canadian biotech stock hit a 2022 high point on May 11, clocking in at the C$0.42 level. |
2. Sirona Biochem (TSXV:SBM) | Market cap: C$56.237 million; year-to-date gain: 17.95 percent Sirona Biochem’s platform for developing safer, more effective cosmetic and pharmaceutical active ingredients is based on proprietary fluorination chemistry developed by the company’s wholly owned French subsidiary, called TFChem. Sirona’s pipeline of products includes therapeutics targeting diabetes, anti-inflammatories and anti-infectives; cosmeceuticals such as anti-aging and depigmenting agents (skin lighteners); and biological ingredients such as inducers and adjuvants for biological development and preservation. In mid-June, the biotech company announced a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie (NYSE:ABBV) company. "We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica™, a leader in the science of skin rejuvenation," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing." Company shares reached a year-to-date high of C$0.35 on June 20. |
3. Ceapro (TSXV:CZO) | Market cap: C$43.505 million; year-to-date gain: 9.09 percent Ceapro is a growth-stage biotech firm that is developing proprietary extraction technology to isolate active ingredients from oats and other plant resources for the healthcare and cosmetic industries. The company is leveraging its expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. In May, Ceapro released its Q1 financials, highlighting sales totaling C$6,172,000 for the quarter, up 31 percent from the same period the previous year. Shares marked a year-to-date high of C$0.67 on May 26. |
Click here to read the latest top Canadian biotech stocks article.
Although it’s not as large as the US biotech industry, the Canadian biotech market is still making a name for itself on the global investment stage in terms of size and opportunities.
In recent years, tech advancements in drug research and development have helped the biotech sector worldwide become a “real industry” that has brought “spectacular” returns for mid-cap companies, according to Jessica Chutter, managing director and chairman of biotechnology investment banking with Morgan Stanley (NYSE:MS).
Looking specifically at Canada, in 2021, the country's government committed to investing C$2.2 billion over seven years toward “growing a strong, competitive biomanufacturing and life sciences sector” through a strategy that includes “foster(ing) the growth of Canadian life sciences firms.”
Although 2021 was a rough year for biotech companies, many of the top Canadian biotech stocks managed to perform well, and some have continued that solid performance into 2022.
Below the Investing News Network profiles the three top Canadian biotech stocks on the TSXV. TSX- and CSE-listed stocks were considered, but didn’t make the cut. Yearly performance and share price data was compiled on July 12, 2022, using TradingView’s stock screener. All top Canadian biotech stocks listed had market caps between C$10 million and C$500 million at that time.
1. Hemostemix (TSXV:HEM)
Market cap: C$16.722 million; year-to-date gain: 37.5 percent
Hemostemix is a clinical-stage autologous stem cell therapy company. Founded in 2003, the firm develops, manufactures and commercializes blood-derived cell therapies from each patient's own blood.
Hemostemix’s lead product, ACP-01, is designed for the treatment of critical limb ischemia, peripheral artery disease, angina, ischemic cardiomyopathy and dilated cardiomyopathy. Shares of the top Canadian biotech stock hit a 2022 high point on May 11, clocking in at the C$0.42 level.
2. Sirona Biochem (TSXV:SBM)
Market cap: C$56.237 million; year-to-date gain: 17.95 percent
Sirona Biochem’s platform for developing safer, more effective cosmetic and pharmaceutical active ingredients is based on proprietary fluorination chemistry developed by the company’s wholly owned French subsidiary, called TFChem. Sirona’s pipeline of products includes therapeutics targeting diabetes, anti-inflammatories and anti-infectives; cosmeceuticals such as anti-aging and depigmenting agents (skin lighteners); and biological ingredients such as inducers and adjuvants for biological development and preservation.
In mid-June, the biotech company announced a global exclusive licensing agreement with Allergan Aesthetics, an AbbVie (NYSE:ABBV) company. "We are very pleased to have finalized terms with a global leader in medical aesthetics and the innovator behind SkinMedica™, a leader in the science of skin rejuvenation," said Dr. Howard Verrico, CEO of Sirona Biochem. "Our most recent clinical trial of TFC-1067 was a collaborative effort with Allergan Aesthetics to demonstrate the clinical potential in topical skin care treatments. This further validates our platform technology as viable for additional commercial products which we are actively pursuing."
Company shares reached a year-to-date high of C$0.35 on June 20.
3. Ceapro (TSXV:CZO)
Market cap: C$43.505 million; year-to-date gain: 9.09 percent
Ceapro is a growth-stage biotech firm that is developing proprietary extraction technology to isolate active ingredients from oats and other plant resources for the healthcare and cosmetic industries. The company is leveraging its expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions.
In May, Ceapro released its Q1 financials, highlighting sales totaling C$6,172,000 for the quarter, up 31 percent from the same period the previous year. Shares marked a year-to-date high of C$0.67 on May 26.
Don’t forget to follow us @INN_LifeScience for real-time news updates!
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Sirona Biochem is a client of the Investing News Network. This article is not paid-for content.
The Beginner’s Guide to Investing in Biotech
Ready to invest in biotech? Our beginner's guide makes it simple to get started.
Download your investing guide today.
Learn About Exciting Investing Opportunities in the Biotech Sector
Your Newsletter Preferences
Melissa Pistilli has been reporting on the markets and educating investors since 2006. She has covered a wide variety of industries in the investment space including mining, cannabis, tech and pharmaceuticals. She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor's degree in English education as well as a master's degree in the teaching of writing, both from Humboldt State University, California.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.
Melissa Pistilli has been reporting on the markets and educating investors since 2006. She has covered a wide variety of industries in the investment space including mining, cannabis, tech and pharmaceuticals. She helps to educate investors about opportunities in a variety of growth markets. Melissa holds a bachelor's degree in English education as well as a master's degree in the teaching of writing, both from Humboldt State University, California.
Learn about our editorial policies.